click below
click below
Normal Size Small Size show me how
PT 201 Ch 10 review
| Question | Answer |
|---|---|
| Absorption | The movement of the drug from the dosage formulation in the blood. |
| Active transport | The movement of the drugs from an area of lower concentration to an area of higher concentration; requires cellular energy. |
| Agonist | Drugs that activate receptors to accelerate or slow normal cellular function. |
| Antagonists | Drugs that bind with receptors but do not activate them. |
| Bioavailability | The relative amount of an administered dose that reaches the general circulation and the rate at which this occurs. |
| Bioequivalency | The comparison of bioavailability between two dosage forms. |
| Biopharmaceutics | The study of the factors associated with products and physiological processes, and the resulting systemic concentrations of drugs. |
| Complexation | When different molecules associate or attach to each other. |
| Disposition | A term sometimes used to refer to all the ADME processes together. |
| Duration of action | The time the drug concentration is above the MEC. |
| Elimination | The process of metabolism and excretion. |
| Enterohepatic cycling | The transfer of drugs and their metabolites from the liver to the bile in the gall bladder, then into the intestine, and then back into circulation. |
| Enzyne | A complex protein that catalyzes chemical reactions. |
| Enzyme induction | The increase in hepatic enzyme activity that results in greater metabolism of drugs. |
| Enzyme inhibition | The decrease in hepatic enzyme activity that results in reduced metabolism of drugs. |
| First pass metabolism | The substantial degradation of an orally administered drug caused by enzyme metabolism in the liver before the drug reaches the systemic circulation. |
| Gastric emptying time | The time a drug will stay in the stomach before it is emptied into the small intestine. |
| Glomerular filtration | The blood filtering process of the nephron. |
| Hydrophilic | Capable of associating with or absorbing water. |
| Hydrophobic | Water repelling;cannot associate with water |
| Lipoidal | Fat-like substance. |
| Metabolite | The substance resulting from the body's transformation of an administered drug. |
| MEC-minimum effective concentration | The blood concentration needed for a drug toproduce a response. |
| MTC-minimum toxic concentration | The upper limit of the therapeutic window. |
| Nepron | The functional unit of the kidney |
| Onset of action | The time MEC(minimum effective concentration) is reached and the response occures |
| Passive diffusion | The movement of drugs from an area of higher concentration to lower conentration. |
| Pharmaceutical alternative | Drug products that contain the same active ingredient but not necessarily in the same salt form, amount, or dosage form. |
| Pharmaceutical equivalent | Drug products that contain identical amounts of the same active ingredient in the same dosage form. |
| Protein binding | The attachment of a drug molecule to a protein, effectively making the drug inactive. |
| Receptor | The cellular material which interacts with the drug. |
| Selective (action) | The characteristic of a drug that makes its action specific tocertain receptors. |
| Site of action | The location where an administered drug produces an effect. |
| Theraputic equivalent | Pharmaceutical equivalents that produce the same effects in patients. |
| Therapeutic window | A drug's blood concentratin range between its MEC (min effective concentration) MTC (min toxic concentration). |